Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients : Results from an international multi-center study exploring DSM-IV and DSM-5 criteria
van de Glind, Geurt (Amsterdam University Medical Center (UMC))
Koeter, Maarten W. J. (Amsterdam University Medical Center (UMC))
van Emmerik-van Oortmerssen, Katelijne (Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands)
Carpentier, Pieter Jan (Reinier van Arkel groep, 's-Hertogenbosch, The Netherlands)
Kaye, Sharlene (National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia)
Degenhardt, Louisa (Melbourne School of Population and Global Health, University of Melbourne, Australia)
Skutle, Arvid (Bergen Clinics Foundation, Bergen, Norway)
Franck, Johan (Karolinska Institutet (Estocolm, Suècia). Department of Clinical Neuroscience)
Bu, Eli Torild Hellandsjø (Bergen Clinics Foundation, Bergen, Norway)
Moggi, Franz (University Hospital of Psychiatry Bern and Department of Psychology, University of Fribourg, Fribourg, Switzerland)
Dom, Geert (Collaborative Antwerp Psychiatry Research Institute (Anvers, Bèlgica))
Verspreet, Sofie (Collaborative Antwerp Psychiatry Research Institute (Anvers, Bèlgica))
Demetrovics, Zsolt (Institute of Psychology, Eötvös Loránd University, Budapest, Hungary)
Kapitány-Fövény, Máté (Nyíro Gyula Hospital Drug Outpatient and Prevention Center, Budapest, Hungary)
Fatséas, Melina (Laboratoire de psychiatrie, Sanpsy CNRS USR 3413, Université de Bordeaux, and Département d'addictologie, CH Ch. Perrens/CHU de Bordeaux, Bordeaux, France)
Auriacombe, Marc (Laboratoire de psychiatrie, Sanpsy CNRS USR 3413, Université de Bordeaux, and Département d'addictologie, CH Ch. Perrens/CHU de Bordeaux, Bordeaux, France)
Schillinger, Arild (Østfold Hospital Trust, Department for Substance Abuse Treatment, Norway)
Møller, Merete (Østfold Hospital Trust, Department for Substance Abuse Treatment, Norway)
Johnson, Brian (Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA)
Faraone, Stephen V. (Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA)
Ramos-Quiroga, Josep Antoni (Hospital Universitari Vall d'Hebron)
Casas Brugué, Miquel (Hospital Universitari Vall d'Hebron)
Allsop, Steve (National Drug Research Institute/Curtin University of Technology, Perth, Australia)
Carruthers, Susan (National Drug Research Institute/Curtin University of Technology, Perth, Australia)
Schoevers, Robert A. (Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands)
Wallhed, Sara (Stockholm Centre for Dependency Disorders, Sweden)
Barta, Csaba (Institute of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, Budapest, Hungary)
Alleman, Peter (Alcohol Treatment Research, Kirchlindach and Ellikon, Switzerland)
Levin, Frances R. (Columbia University/New York State Psychiatric Institute, New York City, NY, USA)
van den Brink, Wim (Amsterdam University Medical Center (UMC))
Konstenius, Maija (Karolinska Institutet (Estocolm, Suècia). Department of Clinical Neuroscience)
Universitat Autònoma de Barcelona

Data:	2013
Resum:	Available studies vary in their estimated prevalence of attention deficit/hyperactivity disorder (ADHD) in substance use disorder (SUD) patients, ranging from 2 to 83%. A better understanding of the possible reasons for this variability and the effect of the change from DSM-IV to DSM-5 is needed. A two stage international multi-center, cross-sectional study in 10 countries, among patients form inpatient and outpatient addiction treatment centers for alcohol and/or drug use disorder patients. A total of 3558 treatment seeking SUD patients were screened for adult ADHD. A subsample of 1276 subjects, both screen positive and screen negative patients, participated in a structured diagnostic interview. Prevalence of DSM-IV and DSM-5 adult ADHD varied for DSM-IV from 5. 4% (CI 95%: 2. 4-8. 3) for Hungary to 31. 3% (CI 95%:25. 2-37. 5) for Norway and for DSM-5 from 7. 6% (CI 95%: 4. 1-11. 1) for Hungary to 32. 6% (CI 95%: 26. 4-38. 8) for Norway. Using the same assessment procedures in all countries and centers resulted in substantial reduction of the variability in the prevalence of adult ADHD reported in previous studies among SUD patients (2-83%→ 5. 4-31. 3%). The remaining variability was partly explained by primary substance of abuse and by country (Nordic versus non-Nordic countries). Prevalence estimates for DSM-5 were slightly higher than for DSM-IV. Given the generally high prevalence of adult ADHD, all treatment seeking SUD patients should be screened and, after a confirmed diagnosis, treated for ADHD since the literature indicates poor prognoses of SUD in treatment seeking SUD patients with ADHD.
Nota:	Altres ajuts: The ICASA Foundation (www.adhdandsubstanceabuse.org) developed the IASP study, and arranged with its participating institutes that each of these institutes would seek funding for their regional process and data sampling efforts. The ICASA Network sought funding for the central organization costs.
Nota:	Altres ajuts: MISSSI/PND0080-2011
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Prevalence ; Substance use disorder ; Attention deficit hyperactivity disorder ; DSM-5 ; Adults
Publicat a:	Drug and alcohol dependence, Vol. 134 (october 2013) , p. 158-166, ISSN 1879-0046

DOI: 10.1016/j.drugalcdep.2013.09.026
PMID: 24156882

20 p, 358.8 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats